Research and Development Agreements - Schedule of Deferred Revenue and Accounts Receivable Balances from the Research and Development Agreements (Detail) - Takeda Pharmaceuticals Inc - USD ($) $ in Thousands |
Jun. 30, 2019 |
Dec. 31, 2018 |
|---|---|---|
| Assets | ||
| Unbilled revenue | $ 0 | $ 240 |
| Liabilities | ||
| Deferred revenue, current | 14,561 | 26,231 |
| Deferred revenue, non-current | 1,664 | 2,670 |
| Total deferred revenue | $ 16,225 | $ 28,901 |
| X | ||||||||||
- Definition Unbilled revenue related to collaborative agreements. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. No definition available.
|
| X | ||||||||||
- Details
|